Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Axerion Therapeutics Inc.

This article was originally published in Start Up

Executive Summary

Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)

You may also be interested in...



Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

MedImmune’s Alzheimer’s Antibody Partnership With Axerion Showcases Virtual Neuroscience R&D Operation

The two companies will work together to optimize and develop preclinical antibodies targeted at blocking amyloid-beta oligomer binding to cellular prion protein.

Galantos Pharma GMBH

Galantos Pharma GMBH is developing a next-generation version of galantamine, an acetylcholinesterase inhibitor that's been on the market as a cognition enhancer since 2000 and went generic in 2008. Galantos' Memogain is a nasal-formulation galantamine prodrug that it says will permeate the blood-brain barrier more efficiently.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC092004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel